TELCYTA
information and resources from the National Cancer Institute
NCI Thesaurus | TELCYTA
(Other name for: TLK286)NCI Thesaurus | TELCYTA
(Other name for: TLK286)
|
|
|
|
news articles
Telik shares fall on downgrade Mar 22, 2006
BusinessWeek ...sell-off followed a research report by Merrill Lynch analyst Eric Ende, who said he believes studies being conducted on Telik's flagship drug Telcyta may not ...
Telik Announces Appointment of Michael K. Inouye as Senior Vice ... Mar 20, 2006
PR Newswire (press release), I look forward to participating in the formation of a commercial organization that complements the robust product candidate pipeline led by TELCYTA(R) and ...
Telik's TELINTRA Demonstrates Positive, Clinically Significant ... Dec 11, 2005
PR Newswire (press release), The company's most advanced drug development candidate is TELCYTA(R) (TLK286), a cancer cell-activated product candidate that is in three Phase 3 registration ...
Telik Announces Presentation at Lazard Capital Markets Life ... Nov 22, 2005
PR Newswire (press release), The company's most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. ...
|
|
